BR9607427A - Inhibition of angiogenes using interleukin 12 - Google Patents

Inhibition of angiogenes using interleukin 12

Info

Publication number
BR9607427A
BR9607427A BR9607427A BR9607427A BR9607427A BR 9607427 A BR9607427 A BR 9607427A BR 9607427 A BR9607427 A BR 9607427A BR 9607427 A BR9607427 A BR 9607427A BR 9607427 A BR9607427 A BR 9607427A
Authority
BR
Brazil
Prior art keywords
angiogenes
interleukin
inhibition
Prior art date
Application number
BR9607427A
Other languages
Portuguese (pt)
Inventor
Emile Eigene Voest
Gary Arthur Truitt
Moses Judah Folkman
Original Assignee
Hoffmann La Roche
Childrens Medical Center
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Hoffmann La Roche, Childrens Medical Center filed Critical Hoffmann La Roche
Publication of BR9607427A publication Critical patent/BR9607427A/en

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/19—Cytokines; Lymphokines; Interferons
    • A61K38/20—Interleukins [IL]
    • A61K38/208—IL-12
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • A61P27/02—Ophthalmic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
    • A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/04—Antibacterial agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Medicinal Chemistry (AREA)
  • Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Organic Chemistry (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Diabetes (AREA)
  • Obesity (AREA)
  • Hematology (AREA)
  • Endocrinology (AREA)
  • Emergency Medicine (AREA)
  • Oncology (AREA)
  • Communicable Diseases (AREA)
  • Pain & Pain Management (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Ophthalmology & Optometry (AREA)
  • Virology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Cardiology (AREA)
  • Zoology (AREA)
  • Rheumatology (AREA)
  • Immunology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Epidemiology (AREA)
  • Dermatology (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)
BR9607427A 1995-02-16 1996-02-07 Inhibition of angiogenes using interleukin 12 BR9607427A (en)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US38938295A 1995-02-16 1995-02-16
PCT/EP1996/000507 WO1996025171A1 (en) 1995-02-16 1996-02-07 Inhibition of angiogenesis using interleukin-12

Publications (1)

Publication Number Publication Date
BR9607427A true BR9607427A (en) 1998-06-23

Family

ID=23538033

Family Applications (1)

Application Number Title Priority Date Filing Date
BR9607427A BR9607427A (en) 1995-02-16 1996-02-07 Inhibition of angiogenes using interleukin 12

Country Status (8)

Country Link
EP (1) EP0809511A1 (en)
JP (1) JPH11500119A (en)
AU (1) AU4788396A (en)
BR (1) BR9607427A (en)
CA (1) CA2212370A1 (en)
FI (1) FI973356A (en)
TR (1) TR199700801T1 (en)
WO (1) WO1996025171A1 (en)

Families Citing this family (15)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6086869A (en) * 1996-11-22 2000-07-11 Toray Industries, Inc. Use of interferon-β or γ to treat retinal edema
US6028060A (en) * 1997-01-29 2000-02-22 Vanderbilt University Treatment of chronic inflammatory diseases with CM101/GBS toxin
US6670337B1 (en) 1998-01-29 2003-12-30 Yeda Reaearch And Development Co., Ltd. Facilitation of wound healing with CM101/GBS toxin
US5981508A (en) * 1997-01-29 1999-11-09 Vanderbilt University Facilitation of repair of neural injury with CM101/GBS toxin
US5858991A (en) 1997-01-29 1999-01-12 Vanderbilt University Facilitation of wound healing with CM101/GBS toxin
US6660258B1 (en) 1997-05-09 2003-12-09 Pharma Pacific Pty Ltd Oromucosal cytokine compositions and uses thereof
JP4856294B2 (en) * 1997-05-27 2012-01-18 アメリカ合衆国政府 Use of nitroxide or a prodrug thereof in the prevention and therapeutic treatment of cancer
AU751524B2 (en) * 1997-11-03 2002-08-22 Trustees Of The University Of Pennsylvania, The Method and compositions for inhibiting angiogenesis and treating cancer
ATE418542T1 (en) 2001-03-29 2009-01-15 Schering Corp ARYLOXIM-PIPERAZINE USABLE AS CCR5 ANTAGONISTS
AU2003292838A1 (en) * 2002-12-27 2004-07-29 Kirin Beer Kabushiki Kaisha Therapeutic agent for wet age-related macular degeneration
EP1608629A1 (en) 2003-03-24 2005-12-28 F. Hoffmann-La Roche Ag Benzyl-pyridazinons as reverse transcriptase inhibitors
CN101291905A (en) 2005-10-19 2008-10-22 弗·哈夫曼-拉罗切有限公司 Phenyl-acetamide nnrt inhibitors
ES2360893T3 (en) 2006-08-16 2011-06-10 F. Hoffmann-La Roche Ag NON-NUCLEOSID INHIBITORS OF REVERSE TRANSCRIPTASE.
KR101475091B1 (en) 2006-12-13 2014-12-22 에프. 호프만-라 로슈 아게 2-(piperidin-4-yl)-4-phenoxy- or phenylamino-pyrimidine derivatives as non-nucleoside reverse transcriptase inhibitors
EP3484500A4 (en) * 2016-07-18 2020-01-08 Neumedicines, Inc Uses of il-12 as a replacement immunotherapeutic

Family Cites Families (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CA2106368A1 (en) * 1992-01-16 1993-07-17 Theodore E. Maione Methods and compositions for treatment of angiogenic disease
JPH06157344A (en) * 1992-02-07 1994-06-03 Childrens Medical Center Corp:The Preparation for blocking new formation of blood vessel and method of blocking new formation of blood vessel

Also Published As

Publication number Publication date
FI973356A0 (en) 1997-08-15
EP0809511A1 (en) 1997-12-03
FI973356A (en) 1997-08-15
AU4788396A (en) 1996-09-04
CA2212370A1 (en) 1996-08-22
JPH11500119A (en) 1999-01-06
TR199700801T1 (en) 1998-03-21
MX9706188A (en) 1997-11-29
WO1996025171A1 (en) 1996-08-22

Similar Documents

Publication Publication Date Title
BR9609772A (en) Reduction of bio-fouling
DE59605821D1 (en) 1/4 SCALLABSORBER
BR9611130A (en) Derivatives of 3-aryl-5-halogen-pyrone
BR9609797A (en) Inhibition of gene expression
BR9609726A (en) Inhibition of gene expression
BR9611475A (en) Acylated 5-aminoisothiaz
BR9607427A (en) Inhibition of angiogenes using interleukin 12
PT874854E (en) ANTIBIOTICS OF CEFALOSPORINA
FR2731885B1 (en) INSTALLATION OF REMOVABLE SHELVES
IT1276799B1 (en) FORMULATIONS OF F-SILICONE
NO961404D0 (en) 4 indolylpiperazinyl derivatives
GB9621852D0 (en) Inhibition of scale
NO960353D0 (en) 4 aminobenzoylguanidinderivater
BR9607046A (en) Derivatives of 3-pyrrolidiliden-2-one-cephalosporins
NO960392D0 (en) 4 merkaptobenzoylguanidinderivater
FI953319A0 (en) Manufacture of dimethylnaphthalene
FR2735986B3 (en) HALTERA EXTENSION
PT761766E (en) ASYMPHETRIC COMPOUNDS OF TRIFENYLENEOXAZINE
UA1112S (en) MICRO-EOM OF WIDE PURPOSE
KR970011853U (en) New form of maryas
KR970027978U (en) Structure of slide hammer
ITMI951551A0 (en) OROSOLUBLE COMPOSITIONS OF N-ACETYLCISTEINE
ITTV950114A0 (en) STRUCTURE OF TABLE-STOOL
KR960031416U (en) Spindle of Thrower
KR970041939U (en) Dust-tightening structure of parts

Legal Events

Date Code Title Description
FA10 Dismissal: dismissal - article 33 of industrial property law